New HIV med stands to boost J&J, Gilead by $500M

The newly minted combination HIV drug from Gilead Sciences and Johnson & Johnson, Complera, is expected to bring in more than $500 million annually. Release | Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.